ALX Oncology Holdings, Inc. (ALXO)
| Market Cap | 2.39B |
| Revenue (ttm) | 1.18M |
| Net Income (ttm) | -50.94M |
| Shares Out | 40.23M |
| EPS (ttm) | -2.76 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 11 |
| Last Price | $60.60 |
| Previous Close | $61.71 |
| Change ($) | -1.11 |
| Change (%) | -1.80% |
| Day's Open | 60.03 |
| Day's Range | 59.25 - 64.17 |
| Day's Volume | 161,725 |
| 52-Week Range | 28.01 - 117.45 |
Alx Oncology Holding sees its Relative Strength Rating enter the 80-plus level. The post Alx Oncology Holding Meets 80-Plus Relative Strength Rating Benchmark appeared first on Investor's Business Daily.
Updated results will be presented from ASPEN-01, the ongoing Phase 1b Study of ALX148 in combination trastuzumab, ramucirumab and paclitaxel in patients with gastric or gastroesophageal junction cancer ...
BURLINGAME, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 chec...
TipRanks analyst ranking service pinpoints Wall Street's best-performing stocks, like Alcon, Semtech, Upstart, and others.
BURLINGAME, Calif., March 18, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 check...
BURLINGAME, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 check...
ALX Oncology (ALXO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
BURLINGAME, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 check...
ALXO is a South Korea origin oncology concern valued at $3 billion on just phase 1 data. They have just a single asset, a CD47 blocker with some special differences.
ALX Oncology is developing a drug that encourages macrophages to "eat" targeted cancer cells. Since releasing an IPO in Summer 2020, their share price has more than tripled, despite only having a single...
BURLINGAME, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkp...
Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider buying can ...
BURLINGAME, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoi...
BURLINGAME, Calif., Dec. 09, 2020 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoi...
BURLINGAME, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoi...
About ALXO
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell; human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma... [Read more...]
| Industry Biotechnology | IPO Date Jul 17, 2020 |
| Stock Exchange NASDAQ | Ticker Symbol ALXO |
Analyst Forecasts
According to 5 analysts, the average rating for ALXO stock is "Strong Buy." The 12-month stock price forecast is 98.43, which is an increase of 62.43% from the latest price.